Weight-Loss Behavioral Program Beneficial for Adults

This article originally appeared here.
Share this content:
Weight-Loss Behavioral Program Beneficial for Adults
Weight-Loss Behavioral Program Beneficial for Adults

FRIDAY, May 5, 2017 (HealthDay News) -- A weight-management group behavioral program is more effective than an intervention comprising brief advice and self-help materials, according to a study published online May 3 in The Lancet.

Amy L. Ahern, Ph.D., from MRC Human Nutrition Research in Cambridge, U.K., and colleagues randomized participants aged 18 years or older with a body mass index of 28 kg/m² or higher from primary care practices to brief advice and self-help materials (211 participants), a weight-management program (Weight Watchers) for 12 weeks (528 participants), or the same program for 52 weeks (528 participants).

The researchers found that the mean weight changes at one year were −3.26 kg in the brief intervention, −4.75 kg in the 12-week program, and −6.76 kg in the 52-week program. Significantly greater weight loss was seen in the behavioral program versus the brief intervention (−2.71 kg); the 52-week program was significantly more effective than the 12-week program (−2.14 kg). At two years, the differences between the groups were still significant. There were no reports of adverse events related to the intervention. The incremental cost-effectiveness ratio compared to the brief intervention was £159 and £91/kg lost for the 52- and 12-week programs, respectively, over two years.

"For adults with overweight or obesity, referral to this open-group behavioral weight-loss program for at least 12 weeks is more effective than brief advice and self-help materials," the authors write.

Several authors disclosed financial ties to the weight-loss industry. Some study funding was provided by Weight Watchers.

Abstract
Full Text
Editorial

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths